The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial / Guarneri, Valentina; Dieci, Maria V; Griguolo, Gaia; Miglietta, Federica; Girardi, Fabio; Bisagni, Giancarlo; Generali, Daniele G; Cagossi, Katia; Sarti, Samanta; Frassoldati, Antonio; Gianni, Lorenzo; Cavanna, Luigi; Pinotti, Graziella; Musolino, Antonino; Piacentini, Federico; Cinieri, Saverio; Prat, Aleix; Conte, PierFranco. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 153(2021), pp. 133-141-141. [10.1016/j.ejca.2021.05.018]

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

Musolino, Antonino
Investigation
;
2021

Abstract

The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2893964
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact